Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads
Author(s) -
Michael H. Gelb,
Frederick S. Buckner
Publication year - 2021
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.1c00091
Subject(s) - malaria , drug discovery , farnesyltransferase , neglected tropical diseases , drug , drug development , clinical trial , tropical disease , medicine , disease , african trypanosomiasis , intensive care medicine , pharmacology , trypanosomiasis , biology , immunology , bioinformatics , pathology , prenylation , biochemistry , enzyme
In this Viewpoint, we provide a brief description of two efforts to develop drugs to treat diseases caused by tropical parasites (Malaria, human African trypanosomiasis and Chagas disease). These efforts are largely based in a University setting but draw heavily on Pharma for a complete progression from drug hit discovery to advancement toward clinical trials. The first case is the development of protein farnesyltransferase inhibitors, and the second case is a series of benzthiazoles, the target of which is being investigated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom